HK1212686A1 - 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途 - Google Patents

嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途

Info

Publication number
HK1212686A1
HK1212686A1 HK16100546.1A HK16100546A HK1212686A1 HK 1212686 A1 HK1212686 A1 HK 1212686A1 HK 16100546 A HK16100546 A HK 16100546A HK 1212686 A1 HK1212686 A1 HK 1212686A1
Authority
HK
Hong Kong
Prior art keywords
amelioration
prevention
treatment
viral disease
pyrimidone derivatives
Prior art date
Application number
HK16100546.1A
Other languages
English (en)
Inventor
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Helmut Buschmann
Stephen Cusack
Mark Smith
Sung-Sau So
Ronald Charles Hawley
Achyutharao Sidduri
Zhuming Zhang
Original Assignee
Savira Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212686(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Savira Pharmaceuticals Gmbh filed Critical Savira Pharmaceuticals Gmbh
Publication of HK1212686A1 publication Critical patent/HK1212686A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16100546.1A 2013-01-08 2016-01-19 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途 HK1212686A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
HK1212686A1 true HK1212686A1 (zh) 2016-06-17

Family

ID=50070507

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112095.2A HK1211286A1 (zh) 2013-01-08 2015-12-08 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途
HK16100546.1A HK1212686A1 (zh) 2013-01-08 2016-01-19 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15112095.2A HK1211286A1 (zh) 2013-01-08 2015-12-08 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途

Country Status (21)

Country Link
US (1) US9045486B2 (zh)
EP (1) EP2943495B1 (zh)
JP (1) JP2016518305A (zh)
KR (1) KR20150103285A (zh)
CN (1) CN104918942A (zh)
AR (1) AR094378A1 (zh)
AU (1) AU2014204889A1 (zh)
BR (1) BR112015012693A2 (zh)
CA (1) CA2894642A1 (zh)
CL (1) CL2015001916A1 (zh)
CR (1) CR20150337A (zh)
EA (1) EA201591291A1 (zh)
HK (2) HK1211286A1 (zh)
IL (1) IL239656A0 (zh)
MA (1) MA38323B1 (zh)
MX (1) MX2015008293A (zh)
PE (1) PE20151722A1 (zh)
PH (1) PH12015501517A1 (zh)
SG (1) SG11201503946UA (zh)
TW (1) TW201443053A (zh)
WO (1) WO2014108406A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PH12015501492A1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
EP4219508B1 (en) 2015-04-28 2024-06-05 Shionogi & Co., Ltd Substituted polycyclic pyridone derivative and prodrug thereof
PL3290424T3 (pl) 2015-04-28 2023-05-08 Shionogi & Co., Ltd Podstawione policykliczne pochodne pirydonu i ich prolek
WO2017072341A1 (en) 2015-10-30 2017-05-04 F. Hoffmann-La Roche Ag Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2881776T3 (es) * 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
JP6957518B2 (ja) * 2016-05-20 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物
HUE049918T2 (hu) 2016-05-31 2020-11-30 Kalvista Pharmaceuticals Ltd Pirazol-származékok mint plazma kallikrein inhibitorok
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN110494141A (zh) 2016-08-10 2019-11-22 盐野义制药株式会社 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B1 (en) 2017-11-29 2024-05-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
PE20210403A1 (es) 2018-02-28 2021-03-02 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de la influenza
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
JP2023519870A (ja) * 2020-03-25 2023-05-15 エスアールアイ インターナショナル インフルエンザウイルスエンドヌクレアーゼの三環式阻害剤
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof
WO2024083933A1 (en) 2022-10-19 2024-04-25 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
EP1725554A1 (en) 2004-03-09 2006-11-29 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
JP2009502964A (ja) * 2005-07-27 2009-01-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
LT2444400T (lt) 2009-06-15 2018-06-11 Shionogi & Co., Ltd. Pakeistasis policiklinis karbamoilpiridono darinys
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
TR201810736T4 (tr) 2010-09-24 2018-08-27 Shionogi & Co Substitüe polisiklik karbamoil piridon derivatı ön-ilacı.

Also Published As

Publication number Publication date
BR112015012693A2 (pt) 2017-07-11
CL2015001916A1 (es) 2016-01-22
PH12015501517A1 (en) 2015-11-09
US9045486B2 (en) 2015-06-02
KR20150103285A (ko) 2015-09-09
MA38323B1 (fr) 2018-05-31
CN104918942A (zh) 2015-09-16
SG11201503946UA (en) 2015-09-29
TW201443053A (zh) 2014-11-16
CR20150337A (es) 2015-11-02
EP2943495B1 (en) 2016-12-28
HK1211286A1 (zh) 2016-05-20
AR094378A1 (es) 2015-07-29
WO2014108406A1 (en) 2014-07-17
EP2943495A1 (en) 2015-11-18
CA2894642A1 (en) 2014-07-17
EA201591291A1 (ru) 2015-12-30
MA38323A1 (fr) 2017-02-28
AU2014204889A1 (en) 2015-06-11
PE20151722A1 (es) 2015-11-19
US20140194431A1 (en) 2014-07-10
JP2016518305A (ja) 2016-06-23
MX2015008293A (es) 2016-06-02
IL239656A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
HK1212686A1 (zh) 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途
HK1211289A1 (zh) 二羥基嘧啶碳酸衍生物以及它們在治療、改善或預防病毒疾病中的用途
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
HK1205128A1 (zh) -氧代-噻唑並吡啶碳酸衍生物和它們在治療、改善或預防病毒疾病中的用途
HK1212688A1 (zh) 吡啶酮衍生物及其在治療、改善或預防病毒疾病中的用途
IL245698A0 (en) Purines are converted in positions 2 and 6 and their use for the treatment of tumors
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
HK1199881A1 (zh) 嘧啶- -酮衍生物及其在治療、減輕或預防病毒疾病中的用途
HK1199640A1 (zh) 雜芳基異羥肟酸衍生物及其在治療、減輕或預防病毒疾病中的用途
HK1211288A1 (zh) 萘啶酮衍生物及其在治療、改善或預防病毒疾病中的用途
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
LT3010496T (lt) Argininas, skirtas panaudoti osteoartrito gydymui ir (arba) prevencijai

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220104